scholarly journals A PARP-1 Feed-Forward Mechanism To Accelerate α-Synuclein Toxicity in Parkinson’s Disease

Biochemistry ◽  
2019 ◽  
Vol 58 (7) ◽  
pp. 859-860 ◽  
Author(s):  
Buyan Pan ◽  
E. James Petersson
PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e3933 ◽  
Author(s):  
Justin Y.D. Lu ◽  
Ping Su ◽  
James E.M. Barber ◽  
Joanne E. Nash ◽  
Anh D. Le ◽  
...  

Clinical evidence points to neuroprotective effects of smoking in Parkinson’s disease (PD), but the molecular mechanisms remain unclear. We investigated the pharmacological pathways involved in these neuroprotective effects, which could provide novel ideas for developing targeted neuroprotective treatments for PD. We used the ETC complex I inhibitor methylpyridinium ion (MPP+) to induce cell death in SH-SY5Y cells as a cellular model for PD and found that nicotine inhibits cell death. Using choline as a nicotinic acetylcholine receptor (nAChR) agonist, we found that nAChR stimulation was sufficient to protect SH-SY5Y cells against cell death from MPP+. Blocking α7 nAChR with methyllycaconitine (MLA) prevented the protective effects of nicotine, demonstrating that these receptors are necessary for the neuroprotective effects of nicotine. The neuroprotective effect of nicotine involves other pathways relevant to PD. Cleaved Poly (ADP-ribose) polymerase-1 (PARP-1) and cleaved caspase-3 were decreased by nicotine in 6-hydroxydopamine (6-OHDA) lesioned mice and in MPP+-treated SH-SY5Y cells. In conclusion, our data indicate that nicotine likely exerts neuroprotective effects in PD through the α7 nAChR and downstream pathways including PARP-1 and caspase-3. This knowledge could be pursued in future research to develop neuroprotective treatments for PD.


2007 ◽  
Vol 357 (3) ◽  
pp. 596-602 ◽  
Author(s):  
Tiago Fleming Outeiro ◽  
Tom N. Grammatopoulos ◽  
Steven Altmann ◽  
Allison Amore ◽  
David G. Standaert ◽  
...  

2016 ◽  
Vol 363 ◽  
pp. 95-96 ◽  
Author(s):  
Maria Grazia Salluzzo ◽  
Filomena I. Cosentino ◽  
Carmelo Romano ◽  
Francesco Scillato ◽  
Maria Concetta Morale ◽  
...  

Science ◽  
2018 ◽  
Vol 362 (6414) ◽  
pp. eaat8407 ◽  
Author(s):  
Tae-In Kam ◽  
Xiaobo Mao ◽  
Hyejin Park ◽  
Shih-Ching Chou ◽  
Senthilkumar S. Karuppagounder ◽  
...  

The pathologic accumulation and aggregation of α-synuclein (α-syn) underlies Parkinson’s disease (PD). The molecular mechanisms by which pathologic α-syn causes neurodegeneration in PD are not known. Here, we found that pathologic α-syn activates poly(adenosine 5′-diphosphate–ribose) (PAR) polymerase-1 (PARP-1), and PAR generation accelerates the formation of pathologic α-syn, resulting in cell death via parthanatos. PARP inhibitors or genetic deletion of PARP-1 prevented pathologic α-syn toxicity. In a feed-forward loop, PAR converted pathologic α-syn to a more toxic strain. PAR levels were increased in the cerebrospinal fluid and brains of patients with PD, suggesting that PARP activation plays a role in PD pathogenesis. Thus, strategies aimed at inhibiting PARP-1 activation could hold promise as a disease-modifying therapy to prevent the loss of dopamine neurons in PD.


2019 ◽  
Author(s):  
Soumitra Ghosh ◽  
Seok Joon Won ◽  
Rebecca Fong ◽  
Nicholas J. M. Butler ◽  
Arianna Moss ◽  
...  

ABSTRACTObjectiveRedox stress, c-Abl activation, and α-synuclein aggregates each independently contribute to neurodegeneration in Parkinson’s disease. Interactions between these factors may underlie convergent and feed-forward mechanisms of disease progression.Methodsα-synuclein aggregate formation was induced in neuronal cultures and mouse substantia nigra by exposure to pre-formed human α-synuclein fibrils or by AAV-mediated over-expression of α-synuclein. Aggregate formation, c-Abl activation, redox stress, and neurodegeneration were evaluated by immunohistochemistry and Western blots, and mouse motor function was evaluated using the rota-rod and pole tests. To suppress redox stress, cultures and mice were treated with N-acetyl cysteine, a thiol repletion agent that supports neuronal glutathione metabolism.ResultsIn primary neuron cultures, the formation of α-synuclein aggregates led to redox stress and c-Abl activation. Redox stress alone, in the absence of α-synuclein aggregates, was also sufficient to induced c-Abl activation. N-acetyl cysteine suppressed redox stress, and likewise suppressed both c-Abl activation and α-synuclein aggregation. A similar pattern was observed in the two mouse models of Parkinson’s disease. In both models, α-synuclein aggregates in the substantia nigra were accompanied by redox stress, c-Abl activation, dopaminergic neurodegeneration and motor impairment, all of which were attenuated in mice treated with oral N-acetyl cysteine.InterpretationThese results indicate that α-synuclein aggregates induce c-Abl activation by a redox stress mechanism. c-Abl in turn promotes α-synuclein aggregation, and this potentially feed-forward process can be blocked by N-acetyl cysteine. The findings thus add mechanistic support for N-acetyl cysteine as a therapeutic for Parkinson’s disease.


2018 ◽  
Vol 4 (2) ◽  
pp. 151-167 ◽  
Author(s):  
Abdalla M. Albeely ◽  
Scott D. Ryan ◽  
Melissa L. Perreault

2007 ◽  
Vol 256 (1-2) ◽  
pp. 68-70 ◽  
Author(s):  
Jon Infante ◽  
Pascual Sánchez-Juan ◽  
Ignacio Mateo ◽  
Eloy Rodríguez-Rodríguez ◽  
Coro Sánchez-Quintana ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document